Gestational trophoblastic diseases comprise a spectrum of interrelated diseases including partial mole, complete mole and gestational choriocarcinoma. Using reverse transcriptase PCR (RT ± PCR) analysis, we identi®ed higher levels of DOC-2/hDab2 expression in the normal trophoblast cells in culture than in choriocarcinoma cell lines. Subsequent study using immunohistochemistry showed high levels of DOC-2/hDab2 protein expression in normal trophoblast tissues but signi®cantly lower levels of expression in gestational trophoblastic disease tissues, particularly in complete mole and choriocarcinoma. When DOC-2/hDab2 was transfected into the choriocarcinoma cell lines, Jar, JEG and BeWo, the stable transfectants showed signi®cantly reduced growth rate in culture. These data suggest that down regulation of DOC-2/hDab2 may play an important role in the development of gestational trophoblastic diseases.
Introduction
Gestational trophoblastic diseases comprise a spectrum of interrelated disease including partial mole, complete mole and gestational choriocarcinoma which have varying propensity for local uterine invasion and metastasis. Because at least part of their genetic background is of paternal origin, gestational trophoblastic diseases are at least partial allografts. Gestational trophoblastic diseases are one of the few human tumors that are highly curable with chemotherapy even in the presence of widespread metastases (Hancock et al., 1997) .
To date early molecular biologic predictors for the development of persistent gestational trophoblastic disease after evacuation of molar pregnancies have not been determined. Cellular proliferation is an intricately regulated process mediated by the coordinated interactions of critical proto-oncogenes and tumor suppressor genes. The dierences between physiological oncogene expression in early placenta and altered oncogene expression in gestational trophoblastic tumors are incompletely understood (Cheung et al., 1993) . Activation of some oncogenes and altered expression of tumor suppressor genes have been demonstrated in gestational trophoblastic tumors (Fulop et al., 1998a,b) . Further analysis of gene expression in placenta and gestational trophoblastic diseases can provide insight into the role played by speci®c proto-oncogenes and tumor suppressor genes in the pathogenesis of these diseases.
Genes that show dierential expression between normal and tumor tissues are likely to function either directly in growth regulation or cellular dierentiation or indirectly as a response to changes in the cellular environment. Several of the tumor suppressor genes characterized to date control growth in epithelial cells (Lee et al., 1987; Miki et al., 1994) . Accumulated evidence suggests that additional growth suppressors will be identi®ed in various cell types. One candidate tumor suppressor gene is the DOC-2/hDab2 gene which has been shown to be expressed in all normal ovarian epithelial cells but signi®cantly down-regulated or absent in all of a series of ovarian carcinoma cell lines tested. Furthermore, it has been shown to suppress ovarian tumor growth in vitro and in vivo (Mok et al., 1994 (Mok et al., , 1998 . The predicted DOC-2/hDab2 protein sequence shows that it contains a phosphotyrosine interacting domain and multiple SH3 binding motifs suggesting that it is a signal transduction molecule (Mok et al., 1998) .
Since DOC-2/hDab2 has also been demonstrated to be highly expressed in normal trophoblastic cells, it is of interest to evaluate whether down-regulation of DOC-2/hDab2 is also involved in the development of trophoblastic diseases. The current study was undertaken to examine the dierential expression pattern of DOC-2/hDab2 transcript and protein in placenta, partial mole, complete mole and choriocarcinoma by Western blot analysis, reverse transcriptase PCR and immunohistochemistry. Furthermore, transfection experiments have also been performed to evaluate the putative tumor suppressor role of DOC-2/hDab2 gene in choriocarcinoma. We suggest that DOC-2/hDab2 may play an important role in the development of trophoblastic diseases.
Results

Immunohistochemistry and Western blot analysis
To evaluate the expression pattern of the DOC-2/ hDab2 protein in normal placenta and gestational trophoblastic disease tissues in vivo, we performed immunohistochemistry in 18 placentas, 17 partial mole, 25 complete moles and 11 choriocarcinomas using the aM2 antibody.
Fourteen (77.7%) of 18 placentas, ®ve (29.4%) of 17 partial moles, three (12%) of 25 complete moles and none of 11 choriocarcinomas showed strong staining for DOC-2/hDab2 protein. Conversely, none of the placenta samples, two (11.7%) partial mole, 17 (68%) complete moles and seven (63.6%) choriocarcinomas were scored as weak or negative for DOC-2/hDab2 antibody immunostaining (Table 1) . The staining for DOC-2/hDab2 in placenta was signi®cantly stronger than in partial mole, complete mole and choriocarcinoma (P50.014; P50.0001; P50.0001, respectively). Partial mole also showed signi®cantly stronger DOC-2/ hDab2 protein expression than complete mole and choriocarcinoma (P50.001; P50.015, respectively). The staining appeared in the cytoplasm of both cytotrophoblast and syncytiotrophoblast but in the latter it was somewhat stronger (Figure 1 ). The intravillous stroma did not display any DOC-2/ hDab2 immunoreactivity.
Western blot analysis using an anti-DOC-2/hDab2 monoclonal antibody generated from amino acid residue 31 ± 44 of the DOC-2/hDab2 protein identi®ed one major 105 kDa protein band in the normal placental cell lines with intensity approximately 10-fold higher than that of the choriocarcinoma cell lines (Figure 2 ).
RT ± PCR
To verify the Western blot results, reverse transcriptase PCR analysis on RNA isolated from the placental cell line and the choriocarcinoma cell lines Jar, JEG-3 and BeWo was also performed. The results demonstrated a stronger 524 bp band (3 ± 4-fold) for DOC-2/hDab2 cDNA in normal placental cells than in all choriocarcinoma cell lines (Figure 3 ) suggesting that DOC-2/ hDab2 message expressed at higher levels in normal placental cells.
MTT cell proliferation study on DOC-2/hDab2 transfected choriocarcinoma cell lines
To evaluate the eect of DOC-2/hDab2 on the growth of choriocarcinoma cells, we transfected full-length DOC-2/hDab2 cDNA in pcDNA3neo expression vector into choriocarcinoma cell lines Jar, JEG-3 and BeWo. Five stably transfected subclones were obtained from Jar (JarDOC2-1, JarDOC2-3, JarDOC2-4, JarDOC2-6 and JarDOC2-9), eight from JEG-3 (JEGDOC2-1, JEGDOC2-2, JEGDOC2-3, JEG-DOC2-5, JEGDOC2-7, JEGDOC2-8, JEGDOC2-9 Number in parenthesis represents percentages of specimens which showed strong or weak/negative immunoreactivity Figure 1 Immunohistochemical localization of DOC-2/hDab2 in normal placenta (a) and choriocarcinoma tissue (b) using aM2 antiserum on paran sections. The syncytiotrophoblast displayed strong immunoreactivity (arrow heads) while the intravillous stroma did not show any immunoreactivity (S). Choriocarcinoma showed much lower levels of DOC-2/hDab2 expression (b). Bar, 50 mm Figure 2 Western blot analysis on one normal placental cell line (3A-SUB-E) and three choriocarcinoma cell lines (Jar, JEG-3 and BeWo) using a monoclonal anti-p96 monoclonal antibody
Tumor suppressor gene DOC-2 in trophoblastic diseases V Fulop et al and JEGDOC2-10) and eight from BeWo (BeWo-DOC2-1, BeWoDOC2-2, BeWoDOC2-3, BeWoDOC2-4, BeWoDOC2-5, BeWoDOC2-8, BeWoDOC2-9, BeWoDOC2-12) cell lines. The presence and the expression of the transfected cDNA in these cell lines were con®rmed by Western blot analysis. The results showed that all the stable DOC-2/hDab2 transfected lines for Jar, JEG-3 and BeWo expressed higher levels of the unspliced 105 kDa DOC-2/hDab2 protein than their stable neo transfected counterparts (Jarneo1, 2, 3 and 4; JEGneo1, 2, 3 and 4; BeWoneo1, 2, 3 and 4). However, the DOC-2/hDab2 protein band of the control placenta cell line remained the strongest (Figure 4 ). On the eighth day, MTT cell proliferation assay showed that the average growth rate for the BeWo DOC-2/hDab2 transfectants (BeWoDOC2-4, BeWoDOC2-5, BeWoDOC2-9 and BeWoDOC2-12) was only 14.5% (P50.0001) of that of the BeWoneo transfectants. Similar study was also performed on the Jar and JEG-3 choriocarcinoma cell lines. The growth rates for Jar and JEG-3 DOC-2/hDab2 transfectants (JarDOC2-1, JarDOC2-4, JarDOC2-6 and JarDOC2-9; JEGDOC2-1, JEGDOC2-3, JEGDOC2-7 and JEG-DOC2-8) were 64.4% (P50.0001) and 85.7% (P50.0002) respectively in comparing to their neo transfected counterparts. These results suggest that DOC-2/hDab2 can suppress choriocarcinoma cell growth in vitro ( Figure 5 ).
Discussion
Using RNA ®ngerprinting, we identi®ed DOC-2/ hDab2 which is preferentially expressed in normal HOSE cells comparing to the ovarian carcinoma cells in vitro and in vivo (Mok et al., 1998) . Homology search shows that it is a human homologue of the mouse p96/mDab2, which has been shown to be a novel phosphoprotein rapidly phosphorylated in macrophages in response to mitogen stimulation of CSF-1 (Xu et al., 1995) . DOC-2 and the p96/mDab2 have several characteristics in common. Both DOC-2/ hDab2 and p96/mDab2 contain a highly conserved PID at the amino-terminus suggesting that they may interact with other proteins phosphorylated on tyrosine (Bork and Margolis, 1995; Kavanaugh and Williams, 1994; Kavanaugh et al., 1995) . The homology between DOC-2/hDab2 and p96/mDab2 is weakened towards the carboxy-terminus of the protein. They both have proline-rich domains in this region which contains multiple SH3 binding motifs Sparks et al., 1994; Viguera et al., 1994) . Xu et al. (1995) has recently demonstrated that the prolinerich domain of mouse p96/mDab2 can interact with the SH3 domains of Grb2 and reduce the binding between Grb2 and Sos suggesting DOC-2/hDab2 may also share the same property and involve in Grb2-Sos signaling pathway.
Using Northern blot analysis, we identi®ed high levels of DOC-2/hDab2 expression in the ovarian surface epithelial cells comprising the germinal epithelium of the ovary (Mok et al., 1998) . However, other organs including brain, stem, heart, and testis also express signi®cant levels of DOC-2/hDab2 transcripts (data not shown). Albertsen et al. (1996) has recently identi®ed DOC-2/hDab2 from a brain stem library and a fetal retina library, and shown DOC-2/hDab2 expression in three normal tissues and Figure 3 RT ± PCR analysis on RNA isolated from one normal placental cell line (3A-SUB-E) and three choriocarcinoma cell lines (Jar, JEG-3 and BeWo) using a primer set speci®c for DOC-2/hDab2. Another primer set speci®c for GAPDH was also used for normalization Figure 5 Histogram showing the percentage of reduction in growth rate in the DOC-2/hDab2 transfected choriocarcinoma cell lines (BeWo, Jar and JEG-3) comparing to their mock neo transfected counterparts. Five stably DOC-2/hDab2 transfected subclones from Jar, eight from JEG-3 and eight from BeWo were used. All cells were seeded at a concentration of 2610 3 cells/well in 100 ml culture medium into 96-well plates. Four replicates for each subclone were used Figure 4 Western blot analysis on four pCDNA3neo transfected cell lines (Jar/neo1, 2, 3 and 4) and four DOC-2/hDab2 transfected lines (Jar/DOC2-1, 2, 3 and 4) using an anti-DOC-2 monoclonal antibody Tumor suppressor gene DOC-2 in trophoblastic diseases V Fulop et al prostrate cancer cell lines by RT ± PCR. These ®ndings suggest that DOC-2/hDab2 expression may not be con®ned to the germinal epithelium of the ovary.
We demonstrated high levels of DOC-2/hDab2 expression in normal trophoblastic cells in culture and down-regulation of both DOC-2/hDab2 transcript and protein in choriocarcinoma cell lines. Immunohistochemistry showed high levels of DOC-2/hDab2 protein expression in normal placenta. The immunoreactivity in partial mole was signi®cantly less than placenta and only low levels of DOC-2/hDab2 expression was observed in complete moles and choriocarcinomas. These staining patterns suggest that down regulation of DOC-2/hDab2 may correlate with the malignant potential of the trophoblastic cells and support the hypothesis that partial mole may progress to complete mole and subsequently to choriocarcinoma.
Southern blot analysis showed that the DOC-2/ hDab2 gene is neither lost nor grossly rearranged (data not shown). However, we cannot rule out the possibilities that down-regulation of DOC-2/hDab2 in choriocarcinoma cells is caused by other genetic changes, such as point mutation or changes in methylation status of the DOC-2/hDab2 promoter. Moreover, reduced DNA-protein interactions of DOC-2/hDab2 promoter with other trans-acting protein factors may also lead to decreased expression of DOC-2/hDab2 in choriocarcinoma cells.
Signi®cantly lower levels of DOC-2/hDab2 expression in various trophoblastic diseases suggest that DOC-2/hDab2 may play an important role in growth and dierentiation of the normal trophoblast cells and down-regulation of DOC-2/hDab2 may be involved in the development of gestational trophoblastic diseases, particularly in complete moles and choriocarcinomas. To evaluate the tumor suppressor role of DOC-2/ hDab2, we isolated stable DOC-2/hDab2 transfectants and studied the growth rate of these transfected subclones by MTT assay. We found that the growth rate of the DOC-2/hDab2 transfected choriocarcinoma cells is signi®cantly lower in culture which suggests that DOC-2/hDab2 can suppress the growth of choriocarcinomas in vitro. The tumor suppressor activity may be attributed to the ability of DOC-2/hDab2 to bind and sequester Grb2 from Sos as suggested by Xu et al. (1995) . Down-regulation of DOC-2/hDab2 in trophoblastic cells from gestational trophoblastic diseases may deregulate Sos-Grb2 binding and contribute to the malignant transformation of the normal placental trophoblastic cells (Xu et al., 1995) . Since Sos is a guanine nucleotide exchange factor for Ras (Chardin et al., 1993) , it will be of interest to evaluate whether down-regulation of DOC-2/hDab2 may lead to Ras activation which results in transformation of normal trophoblastic cells.
Materials and methods
Tissues and cell lines
Archival tissues in paran blocks from 53 patients were collected which consisted of 17 partial hydatidiform moles, 25 complete moles and 11 gestational choriocarcinomas. Control specimens in paran blocks were obtained from 18 aborted normal pregnancies. All tissues were ®xed in formalin in equal conditions. All histopathologic diagnoses were con®rmed by a gynecologic pathologist (D Genest). The gestational ages, de®ned by the duration between the last menstrual period and date of curettage, ranged from 6 ± 16 weeks. Written consent for the collection of tissue samples was obtained according to protocol approved by the Human Subjects Committee of the Brigham and Women's Hospital.
The human placental cell line (3A-SUB-E) and human choriocarcinoma cell lines (Jar, JEG-3, BeWo) were obtained from the American Type Culture Collection (Rockville, MD). The normal placental cells, and the Jar and JEG-3 choriocarcinoma cells were grown and maintained in minimum essential medium Eagle (MEM ± Sigma, St Louis, MO) supplemented with 10% heat inactivated fetal calf serum, L-glutamine (2 mM/ml), penicillin (100 U/ml) and streptomycin (100 mg/ml). BeWo cells were cultured in F12 Ham Kaighn's modi®cation medium (F12K ± Sigma) containing 15% fetal calf serum, L-glutamine, penicillin and streptomycin in the above mentioned concentration. Cells were maintained as exponentially growing monolayer cultures at 378C in a humidi®ed atmosphere of 5% CO 2 and 95% air.
RT ± PCR
Total RNA was isolated from the placental and three choriocarcinoma cell cultures by a standard guanidium thiocyanate-cesium chloride method (Chirgwin et al., 1979) . Reverse transcriptase PCR (RT ± PCR) was performed on these cell lines using the GeneAmp kit (Perkin Elmer, Norwalk, CT). One microgram of total RNA was diluted to a ®nal volume of 20 ml of a master mix containing 5 mM MgCl 2 , 16PCR Buer II, 1 mM dNTP, 1 U/ml RNase Inhibitor, 2.5 U/ml Reverse Transcriptase and 2.5 mM oligo d(T) 16 as the primer. The samples were incubated at room temperature for 10 min to allow for extension of the oligo d(T) 16 . They were then subjected to one cycle of 428C for 30 min, 998C for 5 min, followed by 58C for 5 min. A second master mix containing 1 mM MgCl 2 , 16PCR Buer II, 0.625 U per 25 ml AmpliTaq DNA polymerase and 0.15 mM of the downstream primer (5'-TTCAATCAGTCCCCTTCAATGC-3') and the upstream primer (5'-TCCTGAGGAATGCCAACCTTGC-TGTTG-3') for the DOC-2 transcript (Genosys, The Woodlands, TX) was added to the samples in a total volume of 25 ml. For normalization, a GAPDH primer pair (CLP, San Diego, CA) was also used under the same conditions. Ampli®cation of the cDNA was then carried out using 22 cycles of 958C for 1 min, 558C for 2 min and 748C for 2 min. 5 ml of loading buer was added to 25 ml of the PCR product and samples were electrophoresed on a 1.5% agarose gel.
Western blot analysis
For preparation of protein lysates, cells were ®rst washed three times with phosphate buered saline (PBS) with 1% vanadate, lysed in Laemmli's lysis buer (1% Tritin-100, 21 mg/ml aprotinin, 1 mM phenylmethylsulfonyl¯uoride, 0.5 mg/ml leupeptin, 4.9 mM MgCl 2 , and 1 mM vanadate in PBS) and then centrifuged. The Micro BCA Protein Assay Kit (Pierce) was used for protein quantitation. Cell lysates (25 mg of each protein sample) were diluted with 26SDS sample buer (125 mM Tris, 2.2 M glycerol, 1.42 M bmercaptoethanol, 160 mM SDS, 10 mg/L bromophenol blue, pH 6.8), boiled for 10 min and analysed by SDS ± PAGE (8%). Polypeptides were then transferred to Immobilon-P membrane (Millipore) and incubated with 5% dry milk overnight. The membrane was washed with PBS-0.1% Tween 20 (Sigma) and incubated with a monoclonal antibody generated against a synthetic peptide (GSEKTDEYLLARFKG) (Transduction Laboratories, Tumor suppressor gene DOC-2 in trophoblastic diseases V Fulop et al Lexington, KY) for 1 h. After washing with PBS-0.1% Tween 20, the membrane was incubated with horseradish peroxidase-conjugated donkey anti-mouse IgG (Amersham) for 1 h. Signals were visualized using the ECL Chemiluminescence System (Amersham).
Immunohistochemistry
Localization of the DOC-2/hDab2 protein by immunohistochemistry was performed using the aM2 antiserum raised against a synthetic peptide (IDEKTGVIEHEHPVNKIS) (9). The avidin-biotin complex immunoperoxidase assay was performed on 5 mm sections from formalin ®xed, paran embedded tissues, mounted on Superfrost/Plus microscopic slides (Fisher Scienti®c, Pittsburgh, PA). Sections were deparanized in xylene and hydrated with graded ethanol concentrations and water. The slides were treated with 0.3% hydrogen peroxidase in methanol for 30 min to block the endogenous peroxidase activity and were washed in PBS for 20 min. After blocking nonspeci®c antigens with normal goat serum for 20 min the sections were incubated with rabbit aM2 polyclonal antibody (1 : 4000) at room temperature for 1 h. Then the sections were washed in PBS for 10 min and staining was achieved using a biotin-conjugated secondary goat anti-rabbit antibody solution for 30 min and the ABC horse-radish peroxidase method (Vectastain ELITE ABC kits, Vector Laboratories, Burlingame, California). After washing again in PBS for 10 min the sections were incubated in a diaminobenzidine (DAB) chromogen (Vector Laboratories) for 5 min and washed in water for 10 min. The sections were then dehydrated in ethanol, cleared in xylene and mounted in SP15-500 Permount (Fisher Scienti®c, Pittsburgh, PA). The speci®city of the staining was evaluated and con®rmed by preabsorbing the antibody with the puri®ed peptide (60 mg/ml, Genosys) for 2 h at 378C before applying to the sections. Five to seven sections were randomly taken from each block and were examined by two independent observers. Slides stained with hematoxylin and eosin were available for all specimens. Representative photomicrographs were recorded on Kodak Gold 100 color ®lm (Kodak Co., El Paso, TX). The slides were scored in the absence of any clinical data. Samples were scored semiquantitatively according to the number of positive cells: 7, negative; +, less than 10% of the cells positive; ++, 10 ± 50% of the cells positive; and +++, greater than 50% of the cells positive. The staining intensity was scored as follows: 7, negative; +, weakly positive; ++, moderate positive; +++, strongly positive. A minimum of 1000 cells was counted in at least ®ve high power ®elds.
Isolation of stable DOC-2/hDab2 transfected choriocarcinoma cell lines
The full length DOC-2/hDab2 cDNA (3.2 kb) inserted into the pCDNA3neo eukaryotic expression vector (Invitrogen, La Jolla, CA) in the sense orientation was transfected into the recipient three Jar, JEG and BeWo choriocarcinoma cells by calcium phosphate precipitation method. For control experiments, the vector pCDNA3neo was also transfected into these choriocarcinoma cell lines. All the transfected cells were subjected to G418 (500 mg/ml, BRL, Gaithersburg, MD) selection. Resistant clones representing the stably transfected cells were ring-cloned and expanded. The expression of DOC-2/hDab2 in the stably transfected cells was examined by Western blot analysis.
MTT cell proliferation assay
Four subclones from each of the three pCNA3neo transfected choriocarcinoma cell lines (Jarneo1, 2, 3 and 4; JEGneo1, 2, 3 and 4; BeWoneo1, 2, 3 and 4) and four subclones from each of the three DOC-2/hDab2 transfected choriocarcinoma cell lines (JarDOC2-1, JarDOC2-4, JarDOC2-6 and JarDOC2-9; JEGDOC2-1, JEGDOC2-3, JEGDOC2-7 and JEGDOC2-8; BeWoDOC2-4, BeWo-DOC2-5, BeWoDOC2-9 and BeWoDOC2-12) were seeded at a concentration of 2610 3 cells/well in 100 ml culture medium into 96-well plates. Four replicates for each subclone were used. Culture medium was changed every 3 days and cells were harvested on the eighth day for MTT proliferation assay (Boehringer Mannheim, Indianapolis, IN). Brie¯y, 10 ml of MTT labeling solution was added to each well and incubated at 378C for 4 h. Subsequently 100 ml solubilization solution was added to each well and incubated at 378C overnight. The absorbance of the formagen product was measured at wavelength 550 nm.
Statistical analysis
The immunohistochemical data were analysed with Statview IV statistical software on a Power Macintosh computer. Dierences among groups were determined by analysis of variance (ANOVA) on mean maximum value of intensity and cell count. It was followed by Fisher's protected least signi®cant dierence (PLSD) post-hoc testing. The data of cell proliferation assays were analysed by one tailed one sample t-test using 100% as reference (population) value.
